Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
Year-to-date and Q3 2019 Results
-
AstraZeneca commits $35m to help young people tackle the threat of non-communicable diseases
-
Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes
-
Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
-
Fasenra approved in the US for self-administration in a new pre-filled auto-injector, the Fasenra Pen
-
AstraZeneca divests rights for Losec to Cheplapharm
-
Update on US regulatory review of PT010 in COPD
-
Lynparza more than doubled the time without radiographic disease progression in patients with BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer
-
Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years
-
Lynparza improved the time women lived without disease progression to 22 months in the broad population and to 37 months in HRD-positive patients as 1st-line maintenance treatment with bevacizumab for newly-diagnosed advanced ovarian cancer
Latest articles and press releases
All of our latest press releases and articles are available to explore
